Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Free Cash Flow: 2015-2024

Historic Free Cash Flow for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$354.7 million.

  • Intellia Therapeutics' Free Cash Flow rose 10.67% to -$76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$412.6 million, marking a year-over-year decrease of 13.65%. This contributed to the annual value of -$354.7 million for FY2024, which is 13.09% up from last year.
  • Intellia Therapeutics' Free Cash Flow amounted to -$354.7 million in FY2024, which was up 13.09% from -$408.1 million recorded in FY2023.
  • Intellia Therapeutics' Free Cash Flow's 5-year high stood at -$53.5 million during FY2020, with a 5-year trough of -$408.1 million in FY2023.
  • In the last 3 years, Intellia Therapeutics' Free Cash Flow had a median value of -$354.7 million in 2024 and averaged -$369.9 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Free Cash Flow surged by 51.38% in 2020, and later plummeted by 344.48% in 2021.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Free Cash Flow stood at -$53.5 million in 2020, then slumped by 344.48% to -$237.8 million in 2021, then slumped by 45.86% to -$346.8 million in 2022, then declined by 17.65% to -$408.1 million in 2023, then climbed by 13.09% to -$354.7 million in 2024.